PUBLICATIONS

• Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome.
  JCI insight. 2025 Apr 15; Authors: Mellors PW, Nottingham AN, Casino Remondo B, Shestov M, Planer JD, Peterson AR, Ying Y, Zhou S, Christie JD, Diamond JM, Cantu E, Basil MC, Gill S

• ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders.
  The Journal of clinical investigation. 2025 Apr 15;135(8) Epub 2025 Apr 3; Authors: Sande CM, Chen S, Mitchell DV, Lin P, Abraham DM, Cheng JM, Gebhard T, Deolikar RJ, Freeman C, Zhou M, Kumar S, Bowman M, Bowman RL, Zheng S, Munkhbileg B, Chen Q, Stanley NL, Guo K, Lapite A, Hausler R, Taylor DM, Corines J, Morrissette JJ, Lieberman DB, Yang G, Shestova O, Gill S, Zheng J, Smith-Simmer K, Banaszak LG, Shoger KN, Reinig EF, Peterson M, Nicholas P, Walne AJ, Dokal I, Rosenheck JP, Oetjen KA, Link DC, Gelman AE, Reilly CR, Dutta R, Lindsley RC, Brundige KJ, Agarwal S, Bertuch AA, Churpek JE, Tague LK, Johnson FB, Olson TS, Babushok DV

• Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
  European journal of haematology. 2025 Apr;114(4):626-635 Epub 2024 Dec 26; Authors: Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ

• Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
  Nature medicine. 2025 Apr;31(4):1134-1144 Epub 2025 Jan 20; Authors: Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA

• Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy.
  Transplantation and cellular therapy. 2025 Apr;31(4):228-235 Epub 2025 Jan 21; Authors: Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ

• CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.
  Nature medicine. 2025 Apr;31(4):1171-1182 Epub 2025 Feb 7; Authors: Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, Schmierer M, Kremp M, Ball M, Qureshi R, Schott BH, Sonawane P, DeLong SC, Christiano M, Swaby RF, Abramson S, Locke K, Barton D, Kennedy E, Gill S, Cushing D, Klichinsky M, Condamine T, Abdou Y

• Author Correction: Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models.
  Nature communications. 2025 Mar 19;16(1):2692; Authors: Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, Nagar K, Griffin C, Lian L, Yashiro-Ohtani Y, Ross K, Sloas C, Ball M, Schott B, Sonawane P, Cornell L, Blumenthal D, Chhum S, Minutolo N, Ciccaglione K, Shaw L, Zentner I, Levitsky H, Shestova O, Gill S, Varghese B, Cushing D, Ceeraz DeLong S, Abramson S, Condamine T, Klichinsky M

• Evolving racial/ethnic disparities in AML survival in the novel therapy era.
  Blood advances. 2025 Feb 11;9(3):533-544; Authors: Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C

• Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models.
  Nature communications. 2025 Jan 15;16(1):706; Authors: Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, Nagar K, Griffin C, Lian L, Yashiro-Ohtani Y, Ross K, Sloas C, Ball M, Schott B, Sonawane P, Cornell L, Blumenthal D, Chhum S, Minutolo N, Ciccaglione K, Shaw L, Zentner I, Levitsky H, Shestova O, Gill S, Varghese B, Cushing D, Ceeraz DeLong S, Abramson S, Condamine T, Klichinsky M

• Cytokine-mediated CAR T therapy resistance in AML.
  Nature medicine. 2024 Dec;30(12):3697-3708 Epub 2024 Sep 27; Authors: Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI

• CD45 threads the needle of cytokine cancer immunotherapy.
  Nature immunology. 2024 Oct;25(10):1775-1777; Authors: Wellhausen N, Gill S

• Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors.
  Cancer immunology research. 2024 Sep 3;12(9):1136-1146; Authors: Chang JF, Wellhausen N, Engel NW, Landmann JH, Hopkins CR, Salas-McKee J, Bear AS, Selli ME, Agarwal S, Jadlowsky JK, Linette GP, Gill S, June CH, Fraietta JA, Singh N

• Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia.
  The American journal of cardiology. 2024 Sep 1;226:9-17 Epub 2024 Jul 6; Authors: Kang Y, Lefebvre B, Pamies IM, Gill SI, Doucette AG, Denduluri S, Smith AM, McCurdy S, Luger S, Carver J, Scherrer-Crosbie M

• Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance.
  Nature reviews. Cancer. 2024 Sep;24(9):614-628 Epub 2024 Jul 24; Authors: Wellhausen N, Baek J, Gill SI, June CH

• Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
  Haematologica. 2024 Aug 1;109(8):2732-2737; Authors: Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV

• Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.
  Nature cancer. 2024 Aug;5(8):1227-1249 Epub 2024 May 13; Authors: Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R

• ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.
  Transplantation and cellular therapy. 2024 Aug;30(8):776-787 Epub 2024 May 16; Authors: Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S, Oluwole OO, Rouce RH, Spiegel J, Shah NN, Sharma A, Komanduri K, Gill S

• One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2024 Jul;30(5):802-810 Epub 2023 Aug 21; Authors: Chippendale L, Freyer CW, Carulli A, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, Porter DL, Stadtmauer EA, Loren AW

• Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function.
  Molecular therapy. Oncology. 2024 Jun 20;32(2):200819 Epub 2024 May 24; Authors: Veliz K, Shen F, Shestova O, Shestov M, Shestov A, Sleiman S, Hansen T, O'Connor RS, Gill S

• The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability.
  Research square. 2024 May 7; Authors: Valentić B, Kelly A, Shestov AA, Gan Z, Shen F, Chatoff A, Jaccard A, Crispim CV, Scholler J, Heeke S, Snyder NW, Ghassemi S, Jones N, Gill S, O'Connor RS

• Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
  Transplantation and cellular therapy. 2024 Apr;30(4):415.e1-415.e16 Epub 2024 Jan 17; Authors: Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR

• Hypoimmune cells resist rejection in monkeys.
  Nature biotechnology. 2024 Mar;42(3):380-382; Authors: Borrero Borrego A, Gill S

• Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.
  Leukemia & lymphoma. 2024 Feb;65(2):250-256 Epub 2024 Jan 24; Authors: Freyer CW, Carulli A, Frey NV, Gill SI, Hexner EO, Martin ME, Luger SM, Porter DL, Stadtmauer EA, Loren AW

• Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
  Hematology/oncology clinics of North America. 2023 Dec;37(6):1125-1147 Epub 2023 Jul 11; Authors: Cummins K, Gill S

• Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
  Nature medicine. 2023 Nov;29(11):2954; Authors: Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M

• Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages.
  Immunological reviews. 2023 Nov;320(1):236-249 Epub 2023 Jun 9; Authors: Snyder CM, Gill SI

• Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.
  Science translational medicine. 2023 Sep 20;15(714):eadi1145; Authors: Wellhausen N, O'Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, Garcia KC, Weiner D, June CH, Gill SI

• A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.
  Bone marrow transplantation. 2023 Sep;58(9):991-999 Epub 2023 May 18; Authors: Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JY, Mujeebuddin A, Champlin R, Shpall E, Holtan SG, Alousi A

• CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
  Blood advances. 2023 Aug 22;7(16):4418-4430; Authors: Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, Gill S

• Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
  American journal of hematology. 2023 Aug;98(8):1254-1264 Epub 2023 Jun 19; Authors: Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW

• Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
  Blood advances. 2023 Feb 28;7(4):549-554; Authors: Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop M, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown A, Scott HS, Hiwase D, Godley LA

• Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
  Transplantation and cellular therapy. 2023 Feb;29(2):113-118 Epub 2022 Nov 4; Authors: Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV

• Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review.
  JACC. CardioOncology. 2022 Dec;4(5):563-578 Epub 2022 Dec 20; Authors: Welty NE, Gill SI

• Nomenclature for Cellular and Genetic Therapies: A Need for Standardization.
  Transplantation and cellular therapy. 2022 Dec;28(12):795-801 Epub 2022 Sep 2; Authors: Sharma A, Farnia S, Otegbeye F, Rinkle A, Shah J, Shah NN, Gill S, Maus MV

• Author Correction: Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells.
  Nature. 2022 Dec;612(7941):E22; Authors: Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Loren AW, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH

• Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
  Blood advances. 2022 Nov 8;6(21):5774-5785; Authors: Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL

• Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
  Cancer discovery. 2022 Oct 5;12(10):2372-2391; Authors: Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M

• Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Sep 1;28(17):3804-3813; Authors: Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT

• Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
  Transplantation and cellular therapy. 2022 Sep;28(9):590-596 Epub 2022 Jun 28; Authors: Freyer CW, Babushok DV, Frey NV, Gill SI, Loren AW, Luger SM, Maity A, Martin ME, Plastaras JP, Porter DL, Hexner EO

• Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
  Leukemia & lymphoma. 2022 Aug;63(8):1925-1933 Epub 2022 Feb 20; Authors: Freyer CW, Carulli A, Gier S, Ganetsky A, Timlin C, Schuster M, Babushok D, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz K, Smith J, Stadtmauer EA, Loren AW

• Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
  Blood advances. 2022 Jul 12;6(13):3997-4005; Authors: Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW

• Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
  Leukemia & lymphoma. 2022 Jul;63(7):1645-1650 Epub 2022 Mar 8; Authors: Graveno ME, Carulli A, Freyer CW, Mangan BL, Nietupski R, Loren AW, Frey NV, Porter DL, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Babushok DV, Pratz KW

• Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease.
  American journal of hematology. 2022 Jul;97(7):E273-E276 Epub 2022 Apr 22; Authors: Freyer CW, Gier S, Carulli A, Gill SI, Hexner EO, Loren AW, Martin ME, Porter DL

• Antigen glycosylation regulates efficacy of CAR T cells targeting CD19.
  Nature communications. 2022 Jun 11;13(1):3367; Authors: Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, Haug-Kroeper M, Doray B, Gill S, Ruella M, Hayer KE, Weitzman MD, Green AM, Fluhrer R, Singh N

• Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2022 Jun;28(4):892-897 Epub 2022 Feb 22; Authors: Hatch RV, Freyer CW, Carulli A, Redline G, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz KW, Stadtmauer EA, Loren AW

• Epigenetic engineering empowers T cells.
  Blood. 2022 Apr 7;139(14):2091-2092; Authors: Tandel JV, Gill SI

• Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
  Nature medicine. 2022 Apr;28(4):713-723 Epub 2022 Mar 14; Authors: Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M

• Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
  Current opinion in immunology. 2022 Feb;74:76-84 Epub 2021 Nov 16; Authors: Wellhausen N, Agarwal S, Rommel PC, Gill SI, June CH

• Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells.
  Nature. 2022 Feb;602(7897):503-509 Epub 2022 Feb 2; Authors: Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Loren AW, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH

• Rapid manufacturing of non-activated potent CAR T cells.
  Nature biomedical engineering. 2022 Feb;6(2):118-128 Epub 2022 Feb 21; Authors: Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, Shen F, Cummins KD, Plesa G, Cantu VA, Reddy S, Bushman FD, Gill SI, O'Doherty U, O'Connor RS, Milone MC

• Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2022 Jan 5;30(1):209-222 Epub 2021 Jun 24; Authors: AlJanahi AA, Lazzarotto CR, Chen S, Shin TH, Cordes S, Fan X, Jabara I, Zhou Y, Young DJ, Lee BC, Yu KR, Li Y, Toms B, Tunc I, Hong SG, Truitt LL, Klermund J, Andrieux G, Kim MY, Cathomen T, Gill S, Tsai SQ, Dunbar CE

• Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
  Frontiers in immunology. 2021;12:783305 Epub 2021 Nov 24; Authors: Sloas C, Gill S, Klichinsky M

• Longitudinal Large-Scale Semiquantitative Proteomic Data Stability Across Multiple Instrument Platforms.
  Journal of proteome research. 2021 Nov 5;20(11):5203-5211 Epub 2021 Oct 20; Authors: Lu C, Glisovic-Aplenc T, Bernt KM, Nestler K, Cesare J, Cao L, Lee H, Fazelinia H, Chinwalla A, Xu Y, Shestova O, Xing Y, Gill S, Li M, Garcia B, Aplenc R

• CAR-T cell persistence in the treatment of leukemia and lymphoma.
  Leukemia & lymphoma. 2021 Nov;62(11):2587-2599 Epub 2021 Apr 19; Authors: Gupta A, Gill S

• Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation.
  Transplantation and cellular therapy. 2021 Nov;27(11):934.e1-934.e6 Epub 2021 Jul 30; Authors: Freyer CW, Fradley M, Madnick D, Carver JR, Frey NV, Gill SI, Ky B, Luger SM, Martin ME, McCurdy SR, O'Quinn R, Perl AE, Stadtmauer EA, Loren AW

• Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Oct 10;39(29):3261-3272 Epub 2021 Jun 22; Authors: Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F

• The promise and perils of immunotherapy.
  Blood advances. 2021 Sep 28;5(18):3709-3725; Authors: Lesch S, Gill S

• Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
  Nature medicine. 2021 May;27(5):842-850 Epub 2021 Apr 22; Authors: Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M

• Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.
  Transplantation and cellular therapy. 2021 May;27(5):431.e1-431.e8 Epub 2021 Feb 5; Authors: Freyer CW, Gier S, Moyer ME, Berryman N, Carulli A, Ganetsky A, Timlin C, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy S, Perl AE, Smith J, Luger SM, Stadtmauer EA, Porter DL

• Macrophage-Based Approaches for Cancer Immunotherapy.
  Cancer research. 2021 Mar 1;81(5):1201-1208 Epub 2020 Nov 17; Authors: Anderson NR, Minutolo NG, Gill S, Klichinsky M

• CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2021 Mar;41:1-20; Authors: Gill S, Brudno JN

• DARTs point the way forward in AML.
  Blood. 2021 Feb 11;137(6):720-721; Authors: Gill S

• Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
  JAMA internal medicine. 2021 Feb 1;181(2):195-202; Authors: Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK, Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators

• Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorship.
  Leukemia & lymphoma. 2020 Dec;61(13):3035-3037 Epub 2020 Oct 25; Authors: Mackenzie S, Gill S

• Advances in chimeric antigen receptor T cells.
  Current opinion in hematology. 2020 Nov;27(6):368-377; Authors: Beyar-Katz O, Gill S

• Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
  Leukemia & lymphoma. 2020 Sep;61(9):2200-2207 Epub 2020 Jun 1; Authors: Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM

• Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Sep 1;38(25):2862-2871 Epub 2020 Apr 16; Authors: Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL

• Human chimeric antigen receptor macrophages for cancer immunotherapy.
  Nature biotechnology. 2020 Aug;38(8):947-953 Epub 2020 Mar 23; Authors: Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S

• Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
  Blood advances. 2020 Jul 14;4(13):2866-2870; Authors: Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD

• Cancer immunotherapy comes of age and looks for maturity.
  Nature communications. 2020 Jul 3;11(1):3325; Authors: Finck A, Gill SI, June CH

• Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
  American journal of hematology. 2020 Jul;95(7):792-798 Epub 2020 May 4; Authors: Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, Loren AW

• CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
  Frontiers in oncology. 2020;10:697 Epub 2020 May 6; Authors: Mardiana S, Gill S

• Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.
  Cancer discovery. 2020 Apr;10(4):552-567 Epub 2020 Jan 30; Authors: Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M

• A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
  Blood. 2020 Feb 13;135(7):505-509; Authors: Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill SI

• Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Feb 10;38(5):415-422 Epub 2019 Dec 9; Authors: Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL

• CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.
  The Journal of clinical investigation. 2020 Feb 3;130(2):673-685; Authors: Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD

• How close are we to CAR T-cell therapy for AML?
  Best practice & research. Clinical haematology. 2019 Dec;32(4):101104 Epub 2019 Oct 18; Authors: Gill SI

• Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
  Bone marrow transplantation. 2019 Nov;54(11):1868-1880 Epub 2019 May 15; Authors: Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK

• Bispecific Antibodies in the Treatment of Hematologic Malignancies.
  Clinical pharmacology and therapeutics. 2019 Oct;106(4):781-791 Epub 2019 Mar 29; Authors: Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S

• Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
  Haematologica. 2019 Jul;104(7):1302-1308 Epub 2019 Jun 20; Authors: Cummins KD, Gill S

• Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 May 30;68(12):2003-2009; Authors: Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, Stadtmauer EA, Porter DL

• Will CAR T cell therapy have a role in AML? Promises and pitfalls.
  Seminars in hematology. 2019 Apr;56(2):155-163 Epub 2018 Aug 29; Authors: Cummins KD, Gill S

• Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 Mar;25(3):e76-e85 Epub 2018 Dec 18; Authors: Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK

• 21(st) Century FOX: Toward Gene Therapy for the Regulatory T Cell Deficiency Syndrome IPEX.
  Cell stem cell. 2019 Feb 7;24(2):208-209; Authors: Petty NE, Gill SI

• Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
  Bone marrow transplantation. 2019 Feb;54(2):212-217 Epub 2018 May 24; Authors: Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL

• Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Nov 15;24(22):5502-5515 Epub 2018 Jun 14; Authors: Beyar-Katz O, Gill S

• Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
  Nature medicine. 2018 Oct;24(10):1499-1503 Epub 2018 Oct 1; Authors: Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ

• Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
  Blood. 2018 Sep 6;132(10):1022-1026 Epub 2018 Jun 20; Authors: Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ

• Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
  Leukemia & lymphoma. 2018 Jul;59(7):1539-1553 Epub 2017 Sep 13; Authors: Cummins KD, Gill S

• Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
  Cell. 2018 May 31;173(6):1439-1453.e19; Authors: Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S

• Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
  Nature medicine. 2018 Apr 10;24(4):526; Authors: Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R

• Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.
  Blood advances. 2018 Mar 13;2(5):575-585; Authors: Hosoya H, Levine J, Abt P, Henry D, Porter DL, Gill S

• Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
  Nature medicine. 2018 Mar;24(3):282-291 Epub 2018 Feb 12; Authors: Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R

• Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.
  JCI insight. 2018 Feb 22;3(4); Authors: Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A

• Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.
  Cancer discovery. 2017 Oct;7(10):1154-1167 Epub 2017 Jun 2; Authors: Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S

• Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
  Blood. 2017 Apr 27;129(17):2395-2407 Epub 2017 Feb 28; Authors: Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S

• Improved surfaceome coverage with a label-free nonaffinity-purified workflow.
  Proteomics. 2017 Apr;17(7) Epub 2017 Mar 6; Authors: Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R, Seeholzer SH

• Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Feb;23(2):235-246 Epub 2016 Sep 13; Authors: Kenderian SS, Porter DL, Gill S

• Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy.
  Science translational medicine. 2017 Feb 1;9(375); Authors: Gill S

• CAR T cells engage in anticancer martial arts.
  Science translational medicine. 2017 Jan 18;9(373); Authors: Gill S

• Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.
  Methods in molecular biology (Clifton, N.J.). 2017;1633:267-276; Authors: Kenderian SS, June CH, Gill S

• Chimeric antigen receptor T cell therapy in AML: How close are we?
  Best practice & research. Clinical haematology. 2016 Dec;29(4):329-333 Epub 2016 Oct 18; Authors: Gill S

• Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
  The Journal of clinical investigation. 2016 Oct 3;126(10):3814-3826 Epub 2016 Aug 29; Authors: Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S

• Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies.
  Current hematologic malignancy reports. 2016 Aug;11(4):318-25; Authors: Gill S

• The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jun 1;22(11):2684-96 Epub 2016 Jan 27; Authors: Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA

• Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
  American journal of hematology. 2016 Jun;91(4):426-9; Authors: Kumar AJ, Vassilev P, Loren AW, Luger SM, Reshef R, Gill S, Smith J, Goldstein SC, Hexner E, Stadtmauer EA, Porter D, Frey NV

• Chimeric antigen receptor T cell therapy: 25years in the making.
  Blood reviews. 2016 May;30(3):157-67 Epub 2015 Nov 6; Authors: Gill S, Maus MV, Porter DL

• Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
  Blood. 2016 Mar 3;127(9):1117-27 Epub 2016 Jan 26; Authors: Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV

• Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
  Cancer discovery. 2015 Dec;5(12):1282-95 Epub 2015 Oct 29; Authors: Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A

• High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jul 20;33(21):2392-8 Epub 2015 Jun 8; Authors: Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL

• How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
  Expert opinion on biological therapy. 2015 Jun;15(6):761-6 Epub 2015 Feb 2; Authors: Ruella M, Gill S

• The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 May 1;21(9):1981-3 Epub 2015 Feb 2; Authors: Gill S

• Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Apr;21(4):768-71 Epub 2014 Dec 24; Authors: Bagley SJ, Sehgal AR, Gill S, Frey NV, Hexner EO, Loren AW, Mangan JK, Porter DL, Stadtmauer EA, Reshef R, Luger SM

• Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
  Immunological reviews. 2015 Jan;263(1):68-89; Authors: Gill S, June CH

• Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
  Cancer research. 2014 Nov 15;74(22):6383-9 Epub 2014 Nov 4; Authors: Kenderian SS, Ruella M, Gill S, Kalos M

• Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Nov;20(11):1758-66 Epub 2014 Jul 10; Authors: Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL

• Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
  Blood. 2014 Apr 10;123(15):2343-54 Epub 2014 Mar 4; Authors: Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M

• CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
  Expert opinion on biological therapy. 2014 Jan;14(1):37-49 Epub 2013 Nov 21; Authors: Gill S, Porter DL

• Spontaneous subcapsular splenic hematoma associated with filgrastim in a patient undergoing allogeneic hematopoietic stem cell transplantation.
  The Annals of pharmacotherapy. 2013 May;47(5):e22 Epub 2013 Apr 12; Authors: Ganetsky A, Kucharczuk C, Del Percio S, Frey N, Gill S

• T cell-based gene therapy of cancer.
  Translational research : the journal of laboratory and clinical medicine. 2013 Apr;161(4):365-79 Epub 2012 Dec 11; Authors: Gill S, Kalos M

• Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect.
  Annual review of medicine. 2013;64:101-17 Epub 2012 Oct 29; Authors: Gill S, Porter DL

• Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.
  Blood. 2012 Jun 14;119(24):5758-68 Epub 2012 Apr 27; Authors: Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, Negrin RS

• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
  Cell. 2010 Sep 3;142(5):699-713; Authors: Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R

• NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
  Blood. 2010 May 27;115(21):4293-301 Epub 2010 Mar 16; Authors: Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS

• Biology and clinical effects of natural killer cells in allogeneic transplantation.
  Current opinion in oncology. 2010 Mar;22(2):130-7; Authors: Benjamin JE, Gill S, Negrin RS

• Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
  British journal of haematology. 2009 Oct;147(1):83-8 Epub 2009 Aug 19; Authors: Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, Carney DA, Ritchie DS, Davies JM, Seymour JF

• Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Jul;15(7):765-76 Epub 2009 Apr 2; Authors: Gill S, Olson JA, Negrin RS

• What is the real risk of central nervous system involvement in mantle cell lymphoma?
  Leukemia & lymphoma. 2008 Dec;49(12):2237-9; Authors: Gill S, Seymour JF

• Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
  Annals of hematology. 2008 Sep;87(9):727-34 Epub 2008 Apr 10; Authors: Gill S, Lane SW, Crawford J, Cull G, Joske D, Marlton P, Mollee PN, Prince HM, Seymour JF

• What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
  Leukemia & lymphoma. 2008 Sep;49(9):1653-6; Authors: Gill S, Hicks RJ, Seymour JF

• [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
  Clinical lymphoma & myeloma. 2008 Jun;8(3):159-65; Authors: Gill S, Wolf M, Prince HM, Januszewicz H, Ritchie D, Hicks RJ, Seymour JF

• Therapeutic options in mantle cell lymphoma.
  Leukemia & lymphoma. 2008 Mar;49(3):398-409; Authors: Gill S, Ritchie D

• Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Oct 1;25(28):4493-4; Authors: Gill S, Shapiro J, Westerman D, Prince HM